155 related articles for article (PubMed ID: 37112950)
1. Comparison of Kinetics of Antibody Avidity and IgG Subclasses' Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine.
Rastawicki W; Gierczyński R; Zasada AA
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112950
[TBL] [Abstract][Full Text] [Related]
2. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
5. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
6. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
[TBL] [Abstract][Full Text] [Related]
7. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
9. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations.
Akhtar M; Islam MR; Khaton F; Soltana UH; Jafrin SA; Rahman SIA; Tauheed I; Ahmed T; Khan II; Akter A; Khan ZH; Islam MT; Khanam F; Biswas PK; Ahmmed F; Ahmed S; Rashid MM; Hossain MZ; Alam AN; Alamgir ASM; Rahman M; Ryan ET; Harris JB; LaRocque RC; Flora MS; Chowdhury F; Khan AI; Banu S; Shirin T; Bhuiyan TR; Qadri F
Front Immunol; 2023; 14():1309997. PubMed ID: 38173725
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
13. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history.
Kiszel P; Sík P; Miklós J; Kajdácsi E; Sinkovits G; Cervenak L; Prohászka Z
Sci Rep; 2023 Aug; 13(1):13166. PubMed ID: 37574522
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
16. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A
Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935
[TBL] [Abstract][Full Text] [Related]
17. 6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Cham J; Pandey AC; New J; Huynh T; Hong L; Orendain N; Topol EJ; Nicholson LJ
PLoS One; 2022; 17(4):e0266781. PubMed ID: 35436296
[TBL] [Abstract][Full Text] [Related]
18. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
Buhre JS; Pongracz T; Künsting I; Lixenfeld AS; Wang W; Nouta J; Lehrian S; Schmelter F; Lunding HB; Dühring L; Kern C; Petry J; Martin EL; Föh B; Steinhaus M; von Kopylow V; Sina C; Graf T; Rahmöller J; Wuhrer M; Ehlers M
Front Immunol; 2022; 13():1020844. PubMed ID: 36713457
[TBL] [Abstract][Full Text] [Related]
19. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model.
Dehgani-Mobaraki P; Wang C; Floridi A; Floridi E; Dawoodi S; Zaidi AK
Virology; 2023 Jan; 578():111-116. PubMed ID: 36516688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
